Ameriprise
KRTX

Ameriprise’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Ameriprise’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-42,221
Closed -$13.4M – 3999
2023
Q4 		$13.4M Buy
42,221
+8,068
+24% +$1.57M ﹤0.01% 1544
2023
Q3 		$5.77M Buy
34,153
+31,787
+1,343% +$5.98M ﹤0.01% 2174
2023
Q2 		$513K Buy
2,366
+259
+12% +$55.5K ﹤0.01% 3422
2023
Q1 		$383K Buy
2,107
+79
+4% +$15.1K ﹤0.01% 3528
2022
Q4 		$398K Sell
2,028
-65
-3% -$13.9K ﹤0.01% 3490
2022
Q3 		$471K Sell
2,093
-163
-7% -$33K ﹤0.01% 3414
2022
Q2 		$285K Buy
2,256
+667
+42% +$76.7K ﹤0.01% 3580
2022
Q1 		$201K Sell
1,589
-744
-32% -$83.8K ﹤0.01% 3756
2021
Q4 		$306K Sell
2,333
-7
-0.3% -$905 ﹤0.01% 3666
2021
Q3 		$286K Buy
2,340
+26
+1% +$3K ﹤0.01% 3592
2021
Q2 		$264K Buy
2,314
+178
+8% +$20.8K ﹤0.01% 3689
2021
Q1 		$257K Buy
2,136
+39
+2% +$4.42K ﹤0.01% 3643
2020
Q4 		$213K Buy
+2,097
New +$194K ﹤0.01% 3608

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Ameriprise's KRTX Position: Q1 2024 in Review

Ameriprise sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 42,221 shares — an estimated $13.4M sold.

Ameriprise first reported a position in KRTX in Q4 2020 and held it in 13 quarters. The position peaked at $13.4M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Ameriprise reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Ameriprise sold 42,221 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $13.4M.
  • Ameriprise first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2020 and held it in 13 quarters.
  • Ameriprise's Karuna Therapeutics, Inc. Common Stock position peaked at $13.4M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Ameriprise's 13F filing for Q1 2024, filed 15 May 2024.